The role of lymph node dissection in the management of prostate cancer

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 195-202

  Miki, Jun ^a   Egawa, Shin ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Pelvic lymph node dissection; Prostate cancer; Radical prostatectomy

Indexed keywords

CANCER RISK; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE ASSOCIATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL ANATOMY; SURVIVAL RATE; TREATMENT INDICATION;

CARCINOMA, RENAL CELL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; NOMOGRAMS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 80052722269     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0245-z     Document Type: Review

References (45)

1. Fowler Jr. J.E., Whitmore Jr. W.F., The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer 47:2941-2945.
2. Flocks RH, Culp D, Porto R (1959) Lymphatic spread from prostatic cancer. J Urol 81:194-196.
3. Studer UE, Collette L, Sylvester R (2010) Can radical prostatectomy benefit patients despite the presence of regional metastases? Eur Urol 57:762-763 (author reply 763-765).
4. Masterson TA, Bianco FJ Jr, Vickers AJ et al (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320-1324 (discussion 1324-1325).
5. Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121-125. (Pubitemid 44037727)
6. Allaf ME, Palapattu GS, Trock BJ et al (2004) Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172:1840-1844. (Pubitemid 39363069)
7. Bader P, Burkhard FC, Markwalder R et al (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849-854. (Pubitemid 36188105)
8. Messing EM, Manola J, Sarosdy M et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788.
9. Messing EM, Manola J, Yao J et al (2006) Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479. (Pubitemid 43779173)
10. Golimbu M, Morales P, Al-Askari S et al (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617-620. (Pubitemid 9180259)
11. Wawroschek F, Vogt H, Weckermann D et al (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166:1715-1719. (Pubitemid 32953393)
12. Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158:1891-1894. (Pubitemid 27433173)
13. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681-1686. (Pubitemid 34240702)
14. Bader P, Burkhard FC, Markwalder R et al (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514-518 (discussion 518). (Pubitemid 34793284)
15. Clark T, Parekh DJ, Cookson MS et al (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145-147 (discussion 147-148). (Pubitemid 35461573)
16. Weingartner K, Ramaswamy A, Bittinger A et al (1996) Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 156:1969-1971. (Pubitemid 26378028)
17. Briganti A, Chun FK, Salonia A et al (2007) Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 69:147-151. (Pubitemid 46161677)
18. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974. (Pubitemid 28445094)
19. Kakehi Y, Kamoto T, Okuno H et al (2000) Per-operative frozen section examination of pelvic nodes is unnecessary for the majority of clinically localized prostate cancers in the prostatespecific antigen era. Int J Urol 7:281-286. (Pubitemid 30639437)
20. Briganti A, Chun FK, Salonia A et al (2006) Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50:1006-1013. (Pubitemid 44486500)
21. Musch M, Klevecka V, Roggenbuck U et al (2008) Complications of pelvic lymphadenectomy in 1, 380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol 179:923-928 (discussion 928-929).
22. Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251-1265.
23. Partin AW, Kattan MW, Subong EN et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA 277:1445-1451. (Pubitemid 27208886)
24. Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69:1095-1101. (Pubitemid 46891611)
25. Cagiannos I, Karakiewicz P, EasthamJAet al (2003)Apreoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170:1798-1803. (Pubitemid 37254931)
26. Godoy KT, Chong A, Cronin et al (2011) Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (Epub ahead of print).
27. Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019-1026 (discussion 1017-1026).
28. Briganti A, Karakiewicz PI, Chun FK et al (2007) Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 51:1573-1581. (Pubitemid 46634767)
29. Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw 8:162-200.
30. Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57:754-761.
31. Daneshmand S, Quek ML, Stein JP et al (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172:2252-2255. (Pubitemid 39507502)
32. Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N? patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55:261-270.
33. Boorjian SA, Thompson RH, Siddiqui S et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864-870 (discussion 861-870).
34. Cheng L, Zincke H, Blute ML et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66-73. (Pubitemid 32052615)
35. DiMarco DS, Zincke H, Sebo TJ et al (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173:1121-1125. (Pubitemid 40380516)
36. Gofrit ON, Zorn KC, Steinberg GD et al (2008) The Will Rogers phenomenon in urological oncology. J Urol 179:28-33. (Pubitemid 350216727)
37. Schroder FH, Kurth KH, Fossa SD et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 172:923-927. (Pubitemid 39096424)
38. Schroder FH, Kurth KH, Fossa SD et al (2009) Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 55:14-22.
39. Palapattu GS, Allaf ME, Trock BJ et al (2004) Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 172:1860-1864. (Pubitemid 39363074)
40. von Bodman C, Godoy G, Chade DC et al (2010) Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 184:143-148.
41. Han M, Partin AW, Piantadosi S et al (2001) Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166:416-419. (Pubitemid 32652213)
42. Bolla M, van Poppel H, Collette L et al (2005) Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366:572-578. (Pubitemid 41140332)
43. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: longterm followup of a randomized clinical trial. J Urol 181:956-962.
44. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compa with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924-2930.
45. Da Pozzo LF, Cozzarini C, Briganti A et al (2009) Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55:1003- 1011.